";s:4:"text";s:3675:" UU., que habían sido asignadas de manera aleatoria paraThe finding stems from an analysis of data from the Women's Health Initiative trial on 16,608 postmenopausal women, aged 50 to 79, in the United States who had been randomly assigned toEn este ensayo, las mujeres que recibieron información repetida yde haber interrumpido el método a los 12 meses (OR 0,27; IC del 95%: 0,16 a 0,44) que las mujeres que recibieron la orientación habitual.In that trial, women who received repeated, structured information about the(OR 0.27; 95% CI 0.16 to 0.44) than were women who had routine counseling.and to norethisterone enanthate (NET-EN)/estradiol valerate.- Señor Presidente, aprovecho esta oportunidad para informar de lainiciación inmediata con DMPA mostró menos embarazos que un método "puente" antes de la DMPA (OR 0,36; IC del 95%: 0,16 a 0,84).similar a la progesterona, una hormona que los ovarios producen normalmente cada mes como parte del ciclo menstrual.Los investigadores concluyeron que, entre los hombres que recibieron terapia análoga con hormona liberadora de la gonadotrofina para el cáncera las doce semanas para el tratamiento de los sofocos.Among men receiving gonadotrophin-releasing hormone analogueque se fijará para los MRPL armonizados para estas sustancias en consulta con los laboratorios comunitarios de referencia, los laboratorios nacionales de referencia y los Estados miembros.for harmonised MRPLs for these substances has been agreed in consultation with the Community Reference Laboratories, national reference laboratories and Member States. Using an unextracted radioimmunoassay procedure for the assay of medroxyprogesterone acetate in serum, the apparent half-life for medroxyprogesterone acetate following IM administration of medroxyprogesterone acetate injectable suspension is approximately 50 days. Do not take extra medicine to make up the missed dose.Seek emergency medical attention or call the Poison Help line at 1-800-222-1222.Avoid smoking while you are taking this medicine. Medicines are sometimes prescribed for conditions that are not mentioned in patient information leaflets. The effect of hepatic impairment on medroxyprogesterone acetate injectable suspension pharmacokinetics has not been studied. The pathologist should be advised of progestin therapy when relevant specimens are submitted.The following laboratory tests may be affected by progestins including medroxyprogesterone acetate injectable suspension:(a) Plasma and urinary steroid levels are decreased (e.g., progesterone, estradiol, pregnanediol, testosterone, cortisol). It is also used to treat endometriosis, abnormal uterine … Tell your healthcare provider about all of the medicines you take, including prescription and nonprescription medicines, vitamins, and herbal supplements. Altered menstrual bleeding patterns include amenorrhea, irregular or unpredictable bleeding or spotting, prolonged spotting or bleeding, and heavy bleeding. The box on the bottom of the chart shows the chance of getting pregnant for women who do not use birth control and are trying to get pregnant.Do not use medroxyprogesterone acetate injectable suspension if you:Before taking medroxyprogesterone acetate injectable suspension, tell your healthcare provider if you have:If you are breastfeeding or plan to breastfeed, medroxyprogesterone acetate can pass into your breast milk. SDSs are not intended to be used by Pfizer's patients as a replacement for or as a complement to prescribing information (such as package inserts) or the advice of a healthcare professional.